Why Do I Need a Blood Test to Get GLP-1s like Ozempic in Canada?

You've finally decided to try a GLP-1 medication like Ozempic or Wegovy. You've done the research, you're ready to commit, and then your doctor says: "We need to run some blood work first." What seemed like a straightforward prescription now involves lab visits and waiting for results.

Canadian physicians typically require blood work before prescribing GLP-1 medications, and there are important medical and legal reasons why. This testing isn't optional red tape, it's a critical safety step that protects you from potentially serious complications. This guide explains exactly what doctors are checking, why it matters for your health, and how to navigate the process efficiently.

Why Blood Testing Is Required Before GLP-1 Therapy

Pre-treatment blood work serves three essential purposes: establishing your baseline health status, identifying contraindications that would make GLP-1 therapy unsafe, and creating a reference point for monitoring how your body responds to treatment.

GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) work by mimicking hormones that regulate blood sugar and appetite. While remarkably effective for weight loss and diabetes management, these medications interact with existing health conditions in ways that require careful monitoring.

Understanding Kidney Function and GLP-1 Safety

Your kidneys filter waste products from your blood continuously. GLP-1 medications can affect kidney function through several mechanisms, making baseline assessment critical.

These medications slow gastric emptying, the rate at which food leaves your stomach. This often causes nausea and vomiting, especially during the first few weeks of treatment. If you're experiencing frequent nausea and struggling to keep fluids down, dehydration becomes a real concern. When you're already dehydrated and your kidneys are trying to compensate, adding a medication that your kidneys must process can create a problematic situation.

Doctors measure your creatinine level and calculate your eGFR (estimated glomerular filtration rate) to assess kidney health. These values tell your physician whether your kidneys can safely handle the medication. According to Health Canada's product monographs for semaglutide, patients with severely reduced kidney function (eGFR below 30 mL/min/1.73m²) require careful dose adjustments and closer monitoring.

If you have undiagnosed chronic kidney disease, starting treatment without baseline kidney function tests means your doctor has no reference point if problems develop during therapy.

Thyroid Health Considerations

GLP-1 receptor agonists carry a regulatory warning related to thyroid health that requires careful screening before treatment begins.

In animal studies, rats and mice treated with GLP-1 receptor agonists developed thyroid C-cell tumors at doses significantly higher than human therapeutic doses. While studies have not established whether these findings translate to human risk, Health Canada and the FDA required manufacturers to include warnings about potential risk of medullary thyroid carcinoma (MTC) in their product labeling.

MTC is a rare form of thyroid cancer that develops in the C-cells that produce calcitonin. Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) is a genetic condition that increases MTC risk. If you or immediate family members have a history of MTC or MEN 2, GLP-1 medications are contraindicated, meaning they should not be prescribed.

Your doctor will ask about your personal and family medical history and check your thyroid function through blood tests (typically TSH, and sometimes T3 and T4). This establishes a baseline and identifies any existing thyroid abnormalities that need attention before starting treatment.

Pancreatic and Liver Function Monitoring

GLP-1 medications increase insulin secretion from your pancreas and influence how your liver processes glucose and fat. Baseline testing of pancreatic enzymes (lipase and amylase) and liver function (ALT, AST, and bilirubin) creates a reference point for comparison if symptoms develop during treatment.

For example, if you experience severe abdominal pain three months into treatment, your doctor needs to know whether your lipase was 45 U/L at baseline or 180 U/L. A new elevation suggests medication-related pancreatitis requiring immediate attention. A chronically elevated level indicates a pre-existing condition that may or may not be related to treatment.

Many people with obesity have non-alcoholic fatty liver disease, which can cause mildly elevated liver enzymes. Establishing baseline values helps your physician monitor whether your liver function improves with weight loss (as it often does) or whether concerning changes develop that require investigation.

Complete Guide to Required Blood Tests

Canadian physicians typically order a comprehensive metabolic panel before initiating GLP-1 therapy. Standard practice involves testing within the past 3-6 months, though some practitioners (particularly in telehealth settings) prefer results from the past 30 days.

Complete Blood Count (CBC)

• What it measures: Red blood cells, white blood cells, hemoglobin, hematocrit, and platelets.
• Why it matters: While GLP-1 medications don't directly affect blood counts, this test reveals anemia, signs of infection, or blood disorders that might complicate treatment or explain symptoms like fatigue. It establishes baseline values for comparison during treatment.
• Normal ranges: Hemoglobin 135-175 g/L for men, 120-160 g/L for women; white blood cells 4.0-11.0 × 10⁹/L; platelets 150-400 × 10⁹/L.

Hemoglobin A1c (HbA1c)

• What it measures: Your average blood sugar over the past three months by measuring the percentage of hemoglobin with glucose attached.
• Why it matters: This test determines whether you have diabetes, prediabetes, or normal glucose metabolism. Your A1c result affects dosing decisions, treatment goals, and insurance coverage eligibility in Canada. Provincial drug coverage typically requires an A1c of 6.5% or higher (diabetes diagnosis) for GLP-1 medications prescribed for that indication.
• Normal ranges: Below 5.7% is normal; 5.7-6.4% indicates prediabetes; 6.5% or above suggests diabetes (requires confirmation with repeat testing).
• Practical impact: If your A1c is 5.4% (normal) and you're pursuing GLP-1s for weight loss alone, provincial health plans won't cover the medication, and some physicians are reluctant to prescribe off-label without metabolic disease indicators.

Fasting Glucose

• What it measures: Your blood sugar level after fasting for at least 8 hours, providing a snapshot of current glucose control.
• Why it matters: Combined with A1c, fasting glucose gives your doctor a complete picture of your metabolic health. A1c shows the three-month average, while fasting glucose indicates how well your body manages blood sugar right now.
• Normal ranges: 3.9-5.5 mmol/L is normal; 5.6-6.9 mmol/L suggests prediabetes; 7.0 mmol/L or higher indicates diabetes.
• Important: This test requires proper fasting (8-12 hours, water only) for accurate results.

Kidney Function Panel (Creatinine, eGFR, BUN)

• What it measures: Creatinine is a waste product filtered by kidneys; eGFR estimates how much blood your kidneys filter per minute; BUN (blood urea nitrogen) measures another waste product.
• Why it matters: These values indicate how well your kidneys are working. Since GLP-1 medications are processed through your kidneys and can contribute to dehydration (especially initially), your doctor needs to know your kidney function before prescribing.
• Normal ranges: Creatinine 60-110 μmol/L; eGFR above 90 mL/min/1.73m² is normal; BUN 3.0-7.0 mmol/L.
• Clinical significance: eGFR of 60-89 is mildly reduced (stage 2 kidney disease), 30-59 is moderately reduced (stage 3), and below 30 (stage 4) requires significant dose modifications or may preclude certain GLP-1 options.

Liver Function Tests (ALT, AST, Bilirubin)

• What it measures: ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are enzymes released when liver cells are damaged; bilirubin is produced when red blood cells break down and is processed by the liver.
• Why it matters: Elevated liver enzymes are common in obesity due to non-alcoholic fatty liver disease. Your doctor needs baseline values to determine whether your liver is already stressed before adding medication that affects metabolism. These values typically improve as you lose weight.
• Normal ranges: ALT 10-40 U/L; AST 10-34 U/L; bilirubin 3-20 μmol/L.
• What elevations mean: Mildly elevated enzymes (up to 2× normal) are common with fatty liver and usually improve with weight loss. Values above 2-3× normal require additional investigation before starting GLP-1 therapy.

Lipid Panel (Cholesterol, LDL, HDL, Triglycerides)

• What it measures: Total cholesterol, LDL ("bad" cholesterol), HDL ("good" cholesterol), and triglycerides (a type of fat in your blood).
• Why it matters: GLP-1 medications often improve lipid profiles as you lose weight, so baseline values let you track this benefit. Very high triglycerides (above 10 mmol/L) can indicate increased pancreatitis risk that affects treatment decisions.
• Normal ranges: Total cholesterol below 5.2 mmol/L; LDL below 3.4 mmol/L; HDL above 1.0 mmol/L for men, above 1.3 mmol/L for women; triglycerides below 1.7 mmol/L.

Thyroid Stimulating Hormone (TSH)

• What it measures: TSH is produced by your pituitary gland to regulate thyroid hormone production. It's the primary screening test for thyroid disorders.
• Why it matters: Hypothyroidism (underactive thyroid) makes weight loss extremely difficult regardless of medication and should be treated first. Hyperthyroidism (overactive thyroid) creates cardiovascular risks. This test also provides baseline documentation for the thyroid cancer monitoring requirement.
• Normal ranges: 0.4-4.0 mIU/L (though optimal ranges are debated in medical literature).

What Happens If Your Results Show Abnormalities

Abnormal blood test results don't automatically disqualify you from GLP-1 therapy. They typically mean "not yet" or "with modifications" rather than "never." Your doctor will need to address underlying issues, adjust treatment protocols, or provide closer monitoring.

Reduced Kidney Function

• eGFR 60-89 mL/min (Stage 2 CKD): Most physicians proceed with standard GLP-1 dosing while monitoring kidney function more closely during the initial months.
• eGFR 30-59 mL/min (Stage 3 CKD): You're still a candidate, but your doctor will start with a lower dose and monitor you monthly for the first three months. Aggressive attention to hydration is essential, drink water consistently throughout the day, and contact your doctor immediately if you're experiencing persistent nausea or vomiting that prevents fluid intake.
• eGFR below 30 mL/min (Stage 4 CKD): Treatment requires consultation with a nephrologist (kidney specialist). Some GLP-1 medications have more safety data than others for advanced kidney disease. According to product monographs, semaglutide can be used with caution in stage 4 CKD, though clinical judgment about risks versus benefits becomes more complex.

Elevated Liver Enzymes

• ALT/AST up to 2× upper limit of normal: Common in obesity-related fatty liver disease. Most physicians proceed with GLP-1 therapy while monitoring liver function monthly. These values often improve significantly as you lose weight, weight reduction is actually one of the primary treatments for non-alcoholic fatty liver disease.
• ALT/AST above 2-3× normal: Requires additional investigation before starting medication. Your doctor will order liver imaging (ultrasound) and possibly test for viral hepatitis, autoimmune conditions, or other causes of liver inflammation. Once other causes are ruled out and fatty liver is confirmed, GLP-1 therapy may be part of your treatment plan.
• Active hepatitis or cirrhosis: Requires management by a gastroenterologist or hepatologist before considering weight loss medications.

Abnormal Thyroid Function

• Elevated TSH (hypothyroidism): Your doctor will start thyroid hormone replacement (levothyroxine) and recheck in 6-8 weeks. Once your TSH normalizes, you can begin GLP-1 therapy. Untreated hypothyroidism makes weight loss nearly impossible regardless of medication, so addressing this first improves your chances of success.
• Suppressed TSH (hyperthyroidism): Requires evaluation by an endocrinologist. Hyperthyroidism increases heart rate and cardiovascular stress, which GLP-1 side effects (nausea, vomiting, dehydration) can worsen. You'll need your thyroid condition stabilized before starting weight loss medication.
• TSH in normal range with thyroid nodules: May require ultrasound imaging and possibly fine needle aspiration if nodules meet certain size criteria, especially given the thyroid cancer warnings associated with GLP-1 medications.

Elevated A1c or Fasting Glucose

• A1c 5.7-6.4% (prediabetes): Many physicians view this as an appropriate indication for GLP-1 therapy to prevent progression to diabetes. Some provincial drug plans provide coverage for diabetes prevention in this range, though policies vary.
• A1c 6.5% or higher (diabetes): GLP-1 medications are approved for this indication. You qualify for provincial drug coverage under diabetes treatment (though coverage specifics and copayments vary by province and drug plan).

How to Navigate the Testing Process Efficiently

Understanding the system helps you move from consultation to prescription in 1-2 weeks rather than 4-6 weeks. Strategic planning eliminates most delays.

Step-by-Step Timeline

Days 1-2: Obtain requisition

• Schedule an appointment with your family doctor or a walk-in clinic to discuss GLP-1 therapy and request lab requisition
• Alternative: Use a telehealth platform that provides electronic requisitions (many Canadian services now offer this)

Days 2-3: Book lab appointment

• Call your local Lifelabs, Dynacare, or hospital lab to schedule
• Book early morning appointments for fasting tests (arrive at 8:00 AM after fasting overnight)
• Availability varies by location, urban centers often have same-day or next-day availability; rural areas may require 1-2 weeks

Day 3-4: Complete lab work

• Fast 8-12 hours beforehand (water and black coffee are permitted; food, juice, milk, and sugar are not)
• Bring your requisition and health card
• Hydrate well the day before, it makes blood draws easier

Days 5-10: Results processing

• Most labs send results to your doctor within 2-5 business days
• Many labs offer patient portals where you can view results directly
• If you haven't heard within one week, call the lab or your doctor's office

Days 8-14: Follow-up appointment and prescription

• Discuss results with your doctor
• If results are normal, receive prescription
• If results show abnormalities, discuss next steps (additional testing, referrals, or treatment modifications)

Book Labs Before Your Doctor Appointment

If you're certain about pursuing GLP-1 therapy, ask your family doctor for a lab requisition before your full consultation. Complete the blood work, then schedule your follow-up appointment for after results return. This approach consolidates the process into one discussion about results and prescription rather than requiring multiple appointments.

Many walk-in clinics will provide lab requisitions if you explain you're pursuing weight loss medication. Be specific about requesting a complete metabolic panel, kidney function, liver function, lipids, A1c, and TSH so they order everything your eventual prescriber will need.

Consider Telehealth Services with Integrated Lab Testing

Several Canadian telehealth platforms now offer streamlined lab coordination:

• They provide electronic requisitions you can use at any major lab chain (Lifelabs, Dynacare)
• Results are sent directly to your prescribing physician within their system
• Follow-up consultations happen by video once results are available
• The entire process occurs within one coordinated system

These services typically charge $50-150 for the medical consultation if you're paying out of pocket. Lab work may be covered by your provincial health plan depending on your diagnosis and province, or may cost $100-200 privately.

Understand Provincial Coverage for Lab Testing

Coverage for metabolic panels varies significantly depending on whether you have a diabetes diagnosis and which province you live in.

If you have diabetes (A1c 6.5% or higher): All provinces cover necessary metabolic testing through provincial health insurance when ordered by a physician for diabetes management.

If you're pursuing GLP-1s for weight loss without diabetes:

• Ontario: Generally covers metabolic panels when ordered by a physician as medically necessary. OHIP covers most standard blood work.
• British Columbia: MSP covers basic metabolic testing when ordered for medical reasons. Weight management may qualify depending on BMI and comorbidities.
• Alberta: More restrictive for non-diabetes indications. Many tests require private payment ($100-200 for complete panel) unless you have specific medical conditions.
• Quebec: RAMQ coverage varies by indication. Weight loss without metabolic disease often requires private payment.
• Saskatchewan: Coverage falls between Ontario's broader approach and Alberta's restrictions.
• Maritime provinces: Generally follow testing protocols similar to Ontario with provincial health plan coverage for physician-ordered tests.

Call your provincial health services information line before assuming coverage. If paying privately, ask the lab for a cost estimate before proceeding.

Common Mistakes That Cause Delays

Using old lab results: Even if you had blood work six months ago with perfect results, most physicians require recent testing (within 3-6 months, often within 30 days for telehealth services). Metabolic conditions can develop quickly, and outdated results create liability concerns for prescribers.

Not fasting properly: Eating breakfast before your morning lab appointment invalidates glucose and lipid measurements. Your doctor will need to order repeat testing, adding another week to your timeline. Fast for 8-12 hours, water and black coffee are fine, everything else isn't.

Incomplete test panels: If you arrange private lab work before seeing a doctor, you might not order all necessary tests. Some physicians won't accept third-party results they didn't order due to liability concerns. Confirm which tests are required before paying for private lab work.

Missing appointments: Lab appointments often fill up quickly, especially in smaller communities. If you miss your appointment, you may wait another 1-2 weeks for the next available slot.

Not following up on results: Labs send results to your doctor, but clerical errors happen. If you haven't heard anything within one week, call to confirm your doctor received the results and has reviewed them.

Frequently Asked Questions

Can I use blood test results from my last physical?

Possibly, if the tests are recent (within 3-6 months) and include all required components. Check with your physician, requirements vary by provider and clinical situation.

What if I can't fast for 8-12 hours due to medical conditions?

Discuss this with your doctor before your lab appointment. Some tests can be done without fasting, though fasting provides more accurate glucose and lipid measurements. Your doctor may adjust the testing protocol or interpret non-fasting results in context.

Do I need all these tests if I only want GLP-1s for weight loss?

Yes. The testing requirements are based on medication safety, not your treatment indication. GLP-1 medications affect kidney function, blood sugar, and other metabolic processes regardless of why you're taking them.

What if I have borderline results, can I still get a prescription?

Often yes, with modifications. Borderline kidney function may mean starting at a lower dose with closer monitoring. Borderline glucose elevations (prediabetes) actually strengthen the medical case for GLP-1 therapy.

How much does blood work cost if I'm paying privately?

A complete metabolic panel typically costs $100-200 when paying out of pocket, though prices vary by province and lab. Call the lab beforehand for an estimate.

Can I go to any lab in Canada with my requisition?

Major lab chains (Lifelabs, Dynacare) operate in most provinces. Your requisition should be accepted at any location within the lab network. Hospital-based labs also accept external requisitions. Confirm with the specific lab when booking your appointment.

Key Takeaways

Blood testing before GLP-1 therapy is a fundamental safety measure that protects you from serious complications. These tests identify contraindications, establish baseline health markers, and create reference points for monitoring your response to treatment.

The testing process typically adds 1-2 weeks to your timeline, but strategic planning minimizes delays. Obtain your requisition early, book lab appointments promptly, fast properly, and follow up on results proactively.

If your results show abnormalities, work with your physician to address them. Abnormal values usually mean treatment requires modifications rather than complete exclusion. Many conditions that appear in baseline testing actually improve significantly with the weight loss that GLP-1 medications facilitate.

Understanding why these tests matter, and how to navigate the system efficiently, helps you move from consultation to treatment with minimal frustration while ensuring your safety throughout the process.

Sources

• Health Canada. Product Monograph: Ozempic (semaglutide injection). Available at: https://pdf.hres.ca/dpd_pm/00050513.PDF
• Health Canada. Product Monograph: Wegovy (semaglutide injection). Available at: https://pdf.hres.ca/dpd_pm/00065739.PDF
• Diabetes Canada Clinical Practice Guidelines Expert Committee. Pharmacologic Management of Type 2 Diabetes in Adults. Canadian Journal of Diabetes. 2018;42(Suppl 1):S88-S103.
• Ontario Ministry of Health. Schedule of Benefits for Laboratory Services. Available at: https://www.health.gov.on.ca/en/pro/programs/ohip/sob/lab/lab_mn2021.pdf
• Kidney Foundation of Canada. Estimated Glomerular Filtration Rate (eGFR). Available at: https://kidney.ca/KFOC/media/images/PDFs/eGFR-Fact-Sheet.pdf
• Canadian Agency for Drugs and Technologies in Health. Optimal Prescribing and Use of GLP-1 Receptor Agonists for Type 2 Diabetes. 2013.
• Lifelabs. Patient Test Information and Preparation. Available at: https://www.lifelabs.com/patients/test-information/
• BC Ministry of Health. Medical Services Plan: Laboratory Services. Available at: https://www2.gov.bc.ca/gov/content/health/practitioner-professional-resources/msp/physicians/laboratory-services
• Alberta Health Services. Laboratory Services Public Information. Available at: https://www.albertahealthservices.ca/lab/lab.aspx